genitourinary tumours, prostateFinal overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castration-resistant prostate cancer (mCRPC) Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Fizazi, K
  • Hotte, Sebastien
  • Saad, F
  • Alekseev, B
  • Matveev, VB
  • Flechon, A
  • Gravis, G
  • Joly, F
  • Chi, KN
  • Malik, Z
  • Stewart, P
  • Jacobs, C
  • Beer, TM

publication date

  • October 2016